Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012

Matthias Preusser; Frank Winkler; Laurence Collette; Sven Haller; Sandrine Marreaud; Riccardo Soffietti; Martin Klein; Jaap C. Reijneveld; Joerg-Christian Tonn; Brigitta G. Baumert; Paula Mulvenna; Dirk Schadendorf; Renata Duchnowska; Anna Sophie Berghoff; Nancy Lin; David A. Cameron; Yazid Belkacemi; Jacek Jassem; Damien C. Weber

doi:10.1016/j.ejca.2012.07.002

Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012

Matthias Preusser^*, Frank Winkler, Laurence Collette, Sven Haller, Sandrine Marreaud, Riccardo Soffietti, Martin Klein, Jaap C. Reijneveld, Joerg-Christian Tonn, Brigitta G. Baumert, Paula Mulvenna, Dirk Schadendorf, Renata Duchnowska, Anna Sophie Berghoff, Nancy Lin, David A. Cameron, Yazid Belkacemi, Jacek Jassem, Damien C. Weber

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Brain metastases (BM) occur in a significant proportion of cancer patients and are associated with considerable morbidity and poor prognosis. The trial design in BM patients is particularly challenging, as many disease and patient variables, statistical issues, and the selection of appropriate end-points have to be taken into account. During a meeting organised on behalf of the European Organisation for Research and Treatment of Cancer (EORTC), methodological aspects of trial design in BM were discussed. This paper summarises the issues and potential trial strategies discussed during this meeting and may provide some guidance for the design of trials in BM patients.

Original language	English
Pages (from-to)	3439-3447
Journal	European Journal of Cancer
Volume	48
Issue number	18
DOIs	https://doi.org/10.1016/j.ejca.2012.07.002
Publication status	Published - Dec 2012

Keywords

Brain metastases
Clinical trail
Prophylaxis
EORTC

Access to Document

10.1016/j.ejca.2012.07.002

Cite this

Preusser, M., Winkler, F., Collette, L., Haller, S., Marreaud, S., Soffietti, R., Klein, M., Reijneveld, J. C., Tonn, J.-C., Baumert, B. G., Mulvenna, P., Schadendorf, D., Duchnowska, R., Berghoff, A. S., Lin, N., Cameron, D. A., Belkacemi, Y., Jassem, J., & Weber, D. C. (2012). Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. European Journal of Cancer, 48(18), 3439-3447. https://doi.org/10.1016/j.ejca.2012.07.002

@article{3fb7416deb204134ab45e45916468bf1,

title = "Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012",

abstract = "Brain metastases (BM) occur in a significant proportion of cancer patients and are associated with considerable morbidity and poor prognosis. The trial design in BM patients is particularly challenging, as many disease and patient variables, statistical issues, and the selection of appropriate end-points have to be taken into account. During a meeting organised on behalf of the European Organisation for Research and Treatment of Cancer (EORTC), methodological aspects of trial design in BM were discussed. This paper summarises the issues and potential trial strategies discussed during this meeting and may provide some guidance for the design of trials in BM patients. ",

keywords = "Brain metastases, Clinical trail, Prophylaxis, EORTC",

author = "Matthias Preusser and Frank Winkler and Laurence Collette and Sven Haller and Sandrine Marreaud and Riccardo Soffietti and Martin Klein and Reijneveld, {Jaap C.} and Joerg-Christian Tonn and Baumert, {Brigitta G.} and Paula Mulvenna and Dirk Schadendorf and Renata Duchnowska and Berghoff, {Anna Sophie} and Nancy Lin and Cameron, {David A.} and Yazid Belkacemi and Jacek Jassem and Weber, {Damien C.}",

year = "2012",

month = dec,

doi = "10.1016/j.ejca.2012.07.002",

language = "English",

volume = "48",

pages = "3439--3447",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

number = "18",

}

Preusser, M, Winkler, F, Collette, L, Haller, S, Marreaud, S, Soffietti, R, Klein, M, Reijneveld, JC, Tonn, J-C, Baumert, BG, Mulvenna, P, Schadendorf, D, Duchnowska, R, Berghoff, AS, Lin, N, Cameron, DA, Belkacemi, Y, Jassem, J & Weber, DC 2012, 'Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012', European Journal of Cancer, vol. 48, no. 18, pp. 3439-3447. https://doi.org/10.1016/j.ejca.2012.07.002

TY - JOUR

T1 - Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012

AU - Preusser, Matthias

AU - Winkler, Frank

AU - Collette, Laurence

AU - Haller, Sven

AU - Marreaud, Sandrine

AU - Soffietti, Riccardo

AU - Klein, Martin

AU - Reijneveld, Jaap C.

AU - Tonn, Joerg-Christian

AU - Baumert, Brigitta G.

AU - Mulvenna, Paula

AU - Schadendorf, Dirk

AU - Duchnowska, Renata

AU - Berghoff, Anna Sophie

AU - Lin, Nancy

AU - Cameron, David A.

AU - Belkacemi, Yazid

AU - Jassem, Jacek

AU - Weber, Damien C.

PY - 2012/12

Y1 - 2012/12

N2 - Brain metastases (BM) occur in a significant proportion of cancer patients and are associated with considerable morbidity and poor prognosis. The trial design in BM patients is particularly challenging, as many disease and patient variables, statistical issues, and the selection of appropriate end-points have to be taken into account. During a meeting organised on behalf of the European Organisation for Research and Treatment of Cancer (EORTC), methodological aspects of trial design in BM were discussed. This paper summarises the issues and potential trial strategies discussed during this meeting and may provide some guidance for the design of trials in BM patients.

AB - Brain metastases (BM) occur in a significant proportion of cancer patients and are associated with considerable morbidity and poor prognosis. The trial design in BM patients is particularly challenging, as many disease and patient variables, statistical issues, and the selection of appropriate end-points have to be taken into account. During a meeting organised on behalf of the European Organisation for Research and Treatment of Cancer (EORTC), methodological aspects of trial design in BM were discussed. This paper summarises the issues and potential trial strategies discussed during this meeting and may provide some guidance for the design of trials in BM patients.

KW - Brain metastases

KW - Clinical trail

KW - Prophylaxis

KW - EORTC

U2 - 10.1016/j.ejca.2012.07.002

DO - 10.1016/j.ejca.2012.07.002

M3 - Article

C2 - 22883982

SN - 0959-8049

VL - 48

SP - 3439

EP - 3447

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 18

ER -